CRTX - Cortexyme, Inc.
| Previous Close | 38.05 |
| Open | 38.27 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 38.27 - 40.15 |
| 52 Week Range | 19.50 - 47.50 |
| Volume | 67,609 |
| Avg. Volume | 157,839 |
| Market Cap | 1.036B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.34 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.33 |
- Business Wire•8 days ago
Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts
Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board (CAB). Jeffrey Cummings, M.D., Sc.D., David Hosford M.D., Ph.D., Lon Schneider, M.D., M.S., and Pierre N. Tariot, M.D. join the CAB with deep and diverse experience in central nervous system (CNS) drug development.
- Business Wire•17 days ago
Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019
Cortexyme, Inc. (CRTX) today announced that Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at a National Academies of Science, Engineering, and Medicine workshop on the growing understanding of the relationship between pathogens and chronic disease this week. Ms. Lynch will provide an overview of Cortexyme’s work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases during “Breaking Down Silos: The Convergence of Infectious Diseases and Noncommunicable Diseases,” which will be held June 11-12 in New York. In her remarks, Ms. Lynch will review the scientific rationale and data supporting a key role for Porphyromonas gingivalis in the development of Alzheimer’s disease, based on the identification of the bacteria in the brain of Alzheimer’s patients and its ability to cause neurodegeneration, inflammation, and other pathology associated with Alzheimer’s in animal models.
- Business Wire•2 months ago
Cortexyme, Inc. Announces Pricing of Initial Public Offering
Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions. In addition, Cortexyme has granted the underwriters a 30-day option to purchase up to an additional 661,800 shares at the initial public offering price, less the underwriting discounts and commissions.
- Benzinga•2 months ago
IPO Outlook For The Week: Uber (And 11 Others)
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Milestone Pharmaceuticals Inc. (MIST) will issue 5 million shares between ...
- Yahoo Finance Video•13 hours ago
Cortexyme's unique approach to Alzheimer's research
Biopharmaceutical company Cortexyme is currently in a clinical trial stage, researching what they believe is a new way to treat the cause of Alzheimer's disease and other degenerative diseases. Cortexyme Co-Founder, Chairperson and CEO Casey Lynch sits down with Yahoo Finance's Adam Shapiro, Julie Hyman, and Scott Gamm to discuss.